有利三体与ETV6-RUNX1预测低危B-ALL治愈:COG AALL0331试验结果
COG AALL0331试验纳入5377例NCI标准危B-ALL患儿,其中1857例符合低危标准者随机接受标准或强化培门冬酶治疗。全队列6年CCR为94.7%±0.6%,OS为98.7%±0.3%;两臂CCR无显著差异(95.3%±0.8% vs 94.0%±0.8%,P=.13)。结论:基于临床、早期反应和有利细胞遗传学定义的低危患儿,标准COG化疗不强化培门冬酶即可治愈近全部。
要点
- 低危标准包括无髓外病变、第15天骨髓原始细胞<5%、诱导结束MRD<0.1%及有利细胞遗传学。
- 强化培门冬酶未改善6年CCR(P=.13)或OS(P=.99)。
- 低危患者预后显著优于具有相同早期反应但无有利/不良细胞遗传学的标准危患者。
核心结论
- 标准COG低强度化疗不强化培门冬酶可治愈近全部符合低危标准的B-ALL儿童。
研究设计与样本
- COG AALL0331试验于2005-2010年入组5377例NCI标准危B-ALL患儿(年龄1-9岁,WBC<50,000/μL)。
- 1857例符合低危标准者随机接受标准COG低强度化疗或在此基础上于巩固和 interim maintenance 期每3周加用4剂培门冬酶。
- 研究效能设定为检测6年CCR从92%提高至96%(4%绝对改善)。
主要发现
- 全低危队列6年CCR为94.7%±0.6%,OS为98.7%±0.3%。
- 强化培门冬酶组与标准组6年CCR分别为95.3%±0.8%和94.0%±0.8%(P=.13),OS分别为98.1%±0.5%和99.2%±0.3%(P=.99)。
- 与具有相同早期反应特征但无有利或不良细胞遗传学的标准危患者相比,低危患者CCR风险比1.95(P=.0004),OS风险比5.42(P<.0001),低危组显著更优。
关键数值与推荐
- 低危标准:无髓外病变、第15天骨髓原始细胞<5%、诱导结束骨髓MRD<0.1%、有利细胞遗传学(ETV6-RUNX1融合或4、10、17号染色体同时三体)。
临床怎么用
- 符合低危临床、早期反应和有利细胞遗传学标准的B-ALL患儿可采用标准COG低强度化疗,无需强化培门冬酶。
- 该方案可门诊给药且毒性有限,适合作为低危患儿的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Children's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous complete remission (CCR) rate in a low-risk subset of children with standard-risk B-acute lymphoblastic leukemia (ALL). METHODS: AALL0331 enrolled 5,377 patients with National Cancer Institute standard-risk B-ALL (age 1-9 years, WBC < 50,000/μL) between 2005 and 2010. Following a common three-drug induction, a cohort of 1,857 eligible patients participated in the low-risk ALL random assignment. Low-risk criteria included no extramedullary disease, < 5% marrow blasts by day 15, end-induction marrow minimal residual disease < 0.1%, and favorable cytogenetics (ETV6-RUNX1 fusion or simultaneous trisomies of chromosomes 4, 10, and 17). Random assignment was to standard COG low-intensity therapy (including two pegaspargase doses, one each during induction and delayed intensification) with or without four additional pegaspargase doses at 3-week intervals during consolidation and interim maintenance. The study was powered to detect a 4% improvement in 6-year CCR rate from 92% to 96%. RESULTS: The 6-year CCR and overall survival (OS) rates for the entire low-risk cohort were 94.7% ± 0.6% and 98.7% ± 0.3%, respectively. The CCR rates were similar between arms (intensified pegaspargase 95.3% ± 0.8% v standard 94.0% ± 0.8%; P = .13) with no difference in OS (98.1% ± 0.5% v 99.2% ± 0.3%; P = .99). Compared to a subset of standard-risk study patients given identical therapy who had the same early response characteristics but did not have favorable or unfavorable cytogenetics, outcomes were significantly superior for low-risk patients (CCR hazard ratio 1.95; P = .0004; OS hazard ratio 5.42; P < .0001). CONCLUSION: Standard COG therapy without intensified pegaspargase, which can easily be given as an outpatient with limited toxicity, cures nearly all children with B-ALL identified as low-risk by clinical, early response, and favorable cytogenetic criteria.
引用
- Mattano LA, Devidas M, Maloney KW, et al. Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. J Clin Oncol. 2021. PMID: 33739852. doi:10.1200/JCO.20.02370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。